THERAPEUTIC SLTNS INTL - TSOI STOCK NEWS

Therapeutic Solutions International (TSOI) has announced a significant advancement in their research on JadiCells for treating Chronic Obstructive Pulmonary Disease (COPD). The company filed a patent demonstrating that the therapeutic effects of JadiCell can be transferred to naïve animals via a unique B cell population. Key findings indicate that depleting these B cells negates the therapeutic impact and that interleukin-35 is crucial for their function. This development bolsters TSOI's intellectual property in respiratory treatments, potentially enhancing their therapeutic applications for both acute and chronic conditions, including COVID-19 ARDS.

Therapeutic Solutions International (TSOI) has received Institutional Review Board approval to initiate a ten-patient proof-of-concept clinical trial. This trial aims to evaluate the efficacy of FloraStilbene™ in stimulating the immune system of advanced breast cancer patients. The therapy combines pterostilbene with RU-486 to overcome immune suppression, as evidenced by preclinical data in a mouse model.

Dr. James Veltmeyer emphasized the potential of FloraStilbene™ to enhance existing oncology immunotherapies, while CEO Timothy Dixon highlighted the commitment to addressing unmet medical needs in cancer treatment.

Therapeutic Solutions International (TSOI) has launched the Veltmeyer Institute for Advanced Biologics in Elk City, Idaho, aiming to provide patients access to FDA-cleared JadiCell adult stem cells for brain and lung conditions under the Right to Try Law. This initiative is led by Dr. James Veltmeyer, who has treated over 100 patients in the field. The Institute is touted as the only organization offering allogeneic stem cells cleared by the FDA for clinical trials, positioning itself as a premium destination for patients seeking cutting-edge regenerative medicine and immunotherapy.

Therapeutic Solutions International (TSOI) recently announced groundbreaking preclinical results for their FloraVax therapy, which combines RU-486 with cancer-targeting antigens. This innovative approach leverages the immunological similarities between cancer and pregnancy, enhancing the effects of various immunotherapies. The data, already patented, suggests significant immune modulation benefits. The FDA’s 505b2 pathway may expedite commercialization. Experts in the field have noted the potential of RU-486, despite its controversial history, to contribute positively to cancer treatment.

Therapeutic Solutions International (TSOI) has announced the appointment of Famela Ramos as CEO of its spinoff company, Res Nova Bio, Inc., focused on breast cancer immunotherapy. StemVacs-V, their new "off the shelf" cancer immunotherapy, aims to target the blood vessels feeding tumors without the toxic effects of traditional therapies. Ramos, who has extensive experience in clinical research and business development, expressed her commitment to improving breast cancer treatment outcomes. The company is dedicated to leveraging collaborations to enhance shareholder value and expedite the delivery of their innovative solutions to patients.

Therapeutic Solutions International (TSOI) reported significant advancements by its subsidiary, Campbell Neurosciences, Inc. The company successfully completed phase 1/2 clinical trials for the 'Campbell Score', a diagnostic test identifying a biomarker linked to suicidal ideation. This marks a potential breakthrough in diagnosing suicidal tendencies through objective biological markers rather than subjective assessments. Additionally, Campbell is developing a saliva-based testing method for ease of use. The company has also published several patents aimed at therapeutic interventions for suicide prevention and mental health disorders.

Therapeutic Solutions International (TSOI) has announced a significant discovery in stem cell therapy by identifying a specific type of B cell, producing interleukin-10, that may predict responsiveness to JadiCell therapy. This finding could enhance personalized medicine in regenerative treatments. The company is currently conducting a Phase III clinical trial for COVID-19 ARDS and has received INDs for using JadiCells in COPD and Chronic Traumatic Encephalopathy. The clinical relevance of this marker may extend beyond JadiCells, potentially advancing the effectiveness of stem cell therapies.

Therapeutic Solutions International (TSOI) has announced novel findings on the use of tattooing techniques to enhance immune response against multiple sclerosis. The research indicates that using a tattoo gun to deliver microinjections of myelin basic protein peptides, along with dendritic cell maturation inhibitors, significantly suppresses multiple sclerosis symptoms. The unexpected effectiveness of dermal transfection of AIRE and FoxP3 genes in reducing autoimmune pathology was also highlighted. TSOI continues to focus on its Phase III COVID clinical trial while expanding its patent portfolio.

Therapeutic Solutions International (TSOI) reported encouraging preliminary results from a collaboration with the Veltmeyer Institute for Advanced Therapeutics. The trial focused on patients with neurodegenerative diseases like ALS and autism. One patient showed a significant increase in T-regulatory cells, rising from 47% to 77% after treatment. Another young patient diagnosed with autism began speaking for the first time following therapy. The company aims to make stem cell treatments accessible and emphasizes its commitment to following FDA regulations.